Participant flow

Testing GSK2636771 as a Potential Targeted Treatment in Cancers With PTEN Genetic Changes (MATCH-Subprotocol N) · Source last updated 2026-05-27

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups

1. description

   Patients receive PI3K-beta inhibitor GSK2636771 400mg PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. PI3K-beta Inhibitor GSK2636771: Given PO

   id

   FG000

   title

   Treatment (GSK2636771)

periods

1. drop Withdraws

   1. reasons

      1. group Id

         FG000

         num Subjects

         1

      type

      Ineligible

   2. reasons

      1. group Id

         FG000

         num Subjects

         1

      type

      Never start protocol therapy

   3. reasons

      1. group Id

         FG000

         num Subjects

         4

      type

      Adverse Event

   4. reasons

      1. group Id

         FG000

         num Subjects

         14

      type

      Disease Progression

   5. reasons

      1. group Id

         FG000

         num Subjects

         1

      type

      Complicating disease

   6. reasons

      1. group Id

         FG000

         num Subjects

         3

      type

      Withdrawal by Subject

   milestones

   1. achievements

      1. group Id

         FG000

         num Subjects

         24

      type

      STARTED

   2. achievements

      1. group Id

         FG000

         num Subjects

         23

      type

      Started Protocol Therapy

   3. achievements

      1. group Id

         FG000

         num Subjects

         22

      comment

      Primary efficacy analysis set

      type

      Eligible and Treated

   4. achievements

      1. group Id

         FG000

         num Subjects

         0

      type

      COMPLETED

   5. achievements

      1. group Id

         FG000

         num Subjects

         24

      type

      NOT COMPLETED

   title

   Overall Study

pre Assignment Details

Patients whose tumors harboring PTEN mutation/deletion without loss of PTEN protein expression were assigned to sub-protocol N. The mutation status was determined by MATCH central Oncomine assay for all patients in this arm.

recruitment Details

Subprotocol N was activated on February 25, 2016. Twenty-four patients were enrolled on EAY131-N between May 5, 2016, and December 5, 2016. All patients were enrolled on the basis of the results from the NCI-MATCH assay.

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice